Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Features include always present findings: Female infertility, Elevated circulating follicle stimulating hormone level, and Decreased circulating antimullerian hormone circulation; and common findings: Reduced antral follicle count, Secondary amenorrhea, Elevated circulating luteinizing hormone level, and Oligomenorrhea and others.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Hormones | 2 | Secondary amenorrhea, Female infertility |
SYCP2L function has not been fully characterized.
Premature ovarian failure 24 is associated with mutations in the SYCP2L gene on chromosome 6.
Genetic testing for SYCP2L is available. Testing is considered confirmatory for diagnosis.
Biomarker and diagnostic research for premature ovarian failure 24 has been reported in the published literature.
Phenotype severity distribution: 3 always present features, 5 common features.
No clinical trials have been registered for premature ovarian failure 24.
61 publications have been identified in PubMed for premature ovarian failure 24. Research spans Epidemiology / Natural History (36%), Review / Meta-Analysis (23%), and Basic Science / Preclinical (13%).
Research Type | Count | % of Total |
|---|---|---|
Disease patterns and progression | 22 | 36% |
Data assembled from 5 of 12 sources · Last updated Sep 19, 2026, 11:56 AM UTC
Online Mendelian Inheritance in Man
Lab test results | 2 | Elevated circulating luteinizing hormone level, Elevated circulating follicle stimulating hormone level |
Research summaries
14 |
23% |
Laboratory research | 8 | 13% |
Clinical study results | 7 | 11% |
New treatment approaches | 5 | 8% |
Patient case studies | 3 | 5% |
Other research | 1 | 2% |
Testing and diagnosis research | 1 | 2% |
Jiang Q (2026). [PMID: 42204466](https://pubmed.ncbi.nlm.nih.gov/42204466/). *BMC Cardiovasc Disord*. [Review / Meta-Analysis]
Cui Z (2026). [PMID: 41742181](https://pubmed.ncbi.nlm.nih.gov/41742181/). *J Nanobiotechnology*. [Basic Science / Preclinical]
Vicenti R (2026). [PMID: 41633485](https://pubmed.ncbi.nlm.nih.gov/41633485/). *J Minim Invasive Gynecol*. [Clinical Trial Publication]
Grandi G (2026). [PMID: 42132994](https://pubmed.ncbi.nlm.nih.gov/42132994/). *Fam Cancer*. [Epidemiology / Natural History]
Ruan X (2026). [PMID: 41447991](https://pubmed.ncbi.nlm.nih.gov/41447991/). *Maturitas*. [Review / Meta-Analysis]
Martella S (2025). [PMID: 41463270](https://pubmed.ncbi.nlm.nih.gov/41463270/). *Cancers (Basel)*. [Review / Meta-Analysis]
Zhou J (2025). [PMID: 40488366](https://pubmed.ncbi.nlm.nih.gov/40488366/). *Eur J Endocrinol*. [Epidemiology / Natural History]
Liu G (2025). [PMID: 41239508](https://pubmed.ncbi.nlm.nih.gov/41239508/). *J Ovarian Res*. [Basic Science / Preclinical]
Koloutsou ME (2025). [PMID: 40399615](https://pubmed.ncbi.nlm.nih.gov/40399615/). *Hormones (Athens)*. [Case Report / Case Series]
Shen A (2025). [PMID: 40445059](https://pubmed.ncbi.nlm.nih.gov/40445059/). *Afr J Reprod Health*. [Clinical Trial Publication]